Secondary Logo

Journal Logo


Re: Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial.

  • Free

Pharmacogenetics 2000, 10 :583–590

The author affiliations for this paper were incorrectly stated, Clingenix Inc. had no involvement with this article.

The correct author affiliations are as follows:Michael P. Murphya,*, Margaret E. Beamanb, L. Scott Clarka, Matthew Cayouettea, Linda Bensona, David M. Morrisc and Joseph W. PollicaPPGx Inc. Morrisville, NC, bNeurology and Psychiatry Clinical Development and cBioanalysis and Drug Metabolism, Glaxo Wellcome Inc., Research Triangle Park, NC, USA

Correspondence to Joseph W. Polli, Bioanalysis and Drug Metabolism, Glaxo Wellcome Inc., Room MAI.A3666, PO Box 13398, Research Triangle Park, NC 27709–3398, USA Tel: +1 919 483 3221; fax: +1 919 315 4150; e-mail: [email protected] *Current address: 5500 Windmill Lane, Raleigh, NC 27606, USA E-mail: [email protected]

© 2001 Lippincott Williams & Wilkins, Inc.